Mesoblast (MESO) earnings

Healthcare · Biotechnology · Market cap $1.8B

In the quarter ended June 2023, Mesoblast had revenue of $2M, down 3.8% on a year earlier.

Quarterly results

The last 12 quarters from Mesoblast's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.

Quarter endedRevenueGrowthEPS (diluted)GrowthOp. marginFiled
Jun 30, 2023$2M -3.8% — — — 2023-08-31
Mar 31, 2023$2M -3.6% -0.03 — — 2023-05-26
Dec 31, 2022$2M -10.4% -0.03 — — 2023-02-28
Sep 30, 2022$2M -58.2% -0.02 — — 2022-11-28
Jun 30, 2022$2M +12.7% — — — 2022-08-31
Mar 31, 2022$2M +5.0% -0.03 — — 2022-06-03
Dec 31, 2021$2M +6.3% -0.04 — — 2022-02-25
Sep 30, 2021$4M +175.4% -0.03 — — 2021-11-24
Jun 30, 2021$2M +181.5% — — — 2021-08-31
Mar 31, 2021$2M -84.3% -0.04 — — 2021-06-04
Dec 31, 2020$2M +1.6% -4.38 — — 2021-03-02
Sep 30, 2020$1M -92.3% -4.21 — — 2020-11-23
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MESO.
Open MESO in Investingly

Questions

How did Mesoblast do last quarter?

In the quarter ended June 2023, Mesoblast had revenue of $2M, down 3.8% on a year earlier.

From Mesoblast's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.